A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer

On May 15, 2026, HarbourVest Partners disclosed a new position in Generate Biomedicines (NASDAQ:GENB), acquiring 1,722,210 shares in the first quarter. The estimated transaction value is $21.03 million, based on quarterly average pricing.According to a Securities and Exchange Commission (SEC) filing published May 15, 2026, HarbourVest Partners took a new position in Generate Biomedicines during the first quarter of 2026, adding 1,722,210 shares. The estimated transaction value was $21.03 million, based on the average closing price over the quarter. The position was valued at $21.53 million as of March 31, 2026, encompassing both share purchases and price changes.Generate Biomedicines, Inc. applies advanced machine learning to accelerate the discovery and development of new protein therapeutics, integrating computational tools with scalable laboratory processes. The company’s strategy centers on its proprietary Generate Platform, which enables the design of novel drugs that address unmet medical needs beyond the reach of traditional methods.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool